Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing.
Köstek O, Demirel A, Hacıoğlu MB, Tastekin D, Karabulut S, Gündogdu A, Sever N, Ayhan M, Çelebi A, Majidova N, Yaşar A, Ağyol Y, Erel P, Kocaaslan E, Güren AK, Arıkan R, Isık S, Ercelep O, Goksu SS, Alandag C, Bilgetekin İ, Caner B, Sahin AB, Gulmez A, Akagunduz B, Kose F, Kaplan MA, Dogan E, Sakalar T, Guven DC, Gurbuz M, Ergun Y, Karaagac M, Turker S, Ozkul O, Yıldız B, Sahin S, Demiray AG, Sari M, Erdogan B, Hacıbekiroglu İ, Çakmak Öksüzoğlu ÖB, Kilickap S, Bilici A, Bayoglu İV, Topaloglu S, Cicin İ. Köstek O, et al. Among authors: turker s. J Chemother. 2024 Nov;36(7):613-621. doi: 10.1080/1120009X.2024.2305066. Epub 2024 Jan 23. J Chemother. 2024. PMID: 38263804
Worse patient-physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG).
Alkan A, Yaşar A, Güç ZG, Gürbüz M, Başoğlu T, Sezgin Göksu S, Buğdaycı Başal F, Türk HM, Özdemir Ö, Yeşil Çınkır H, Güven DC, Kuş T, Türker S, Koral L, Karakaş Y, Ak N, Paydaş S, Karcı E, Demiray AG, Demir A, Alan Ö, Keskin Ö, Nayır E, Tanrıverdi Ö, Yavuzşen T, Yumuk PF, Ateş Ö, Coşkun HŞ, Turhal S, Çay Şenler F. Alkan A, et al. Among authors: turker s. Eur J Cancer Care (Engl). 2020 Nov;29(6):e13296. doi: 10.1111/ecc.13296. Epub 2020 Aug 30. Eur J Cancer Care (Engl). 2020. PMID: 32864838
Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey.
Bekir Hacioglu M, Kostek O, Karabulut S, Tastekin D, Sezgin Goksu S, Alandag C, Akagunduz B, Bilgetekin I, Caner B, Bilgehan Sahin A, Yildiz B, Kose F, Kaplan MA, Gulmez A, Dogan E, Can Guven D, Gurbuz M, Ergun Y, Karaagac M, Gokcen Demiray A, Turker S, Sakalar T, Ozkul O, Telli TA, Sahin S, Kilickap S, Bilici A, Erdogan B, Cicin I. Bekir Hacioglu M, et al. Among authors: turker s. J BUON. 2020 Jul-Aug;25(4):1897-1903. J BUON. 2020. PMID: 33099930 Free article.
Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer.
Gürbüz M, Akkuş E, Sakin A, Urvay S, Demiray AG, Şahin S, Şakalar T, Erol C, Şendur MAN, Şahin AB, Çubukçu E, Güven DC, Kılıçkap S, Ergün Y, Uncu D, Turhal NS, Üskent N, Yeşil Çınkır H, Demir A, Acar R, Karadurmuş N, Türker S, Altınbaş M, Karaoğlan M, Çay Şenler F. Gürbüz M, et al. Among authors: turker s. Tumori. 2021 Oct;107(5):416-423. doi: 10.1177/0300891620969823. Epub 2020 Nov 9. Tumori. 2021. PMID: 33167790
Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group.
Gürbüz M, Akkuş E, Sakin A, Urvay S, Demiray AG, Şahin S, Şakalar T, Erol C, Şendur MAN, Şahin AB, Çubukçu E, Güven DC, Kılıçkap S, Ergün Y, Uncu D, Turhal NS, Üskent N, Çınkır HY, Demir A, Acar R, Karadurmuş N, Türker S, Altınbaş M, Karaoğlan M, Şenler FÇ. Gürbüz M, et al. Among authors: turker s. J Gastrointest Cancer. 2022 Jun;53(2):282-288. doi: 10.1007/s12029-021-00594-1. Epub 2021 Feb 4. J Gastrointest Cancer. 2022. PMID: 33538958
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study.
Bilici A, Uysal M, Menekse S, Akin S, Yildiz F, Turan M, Sezgin Goksu S, Beypinar I, Sakalar T, Değirmenci M, Erdem D, Basaran G, Olmez OF, Avci N, Tural D, Sakin A, Turker S, Demir A, Temiz S, Kaplan MA, Dogan M, Tanriverdi O, Bilgetekin I, Cinkir HY, Acikgoz O, Paydas S, Uslu R, Turhal S. Bilici A, et al. Among authors: turker s. Cancer Invest. 2022 Feb;40(2):199-209. doi: 10.1080/07357907.2021.2017952. Epub 2021 Dec 22. Cancer Invest. 2022. PMID: 34894960
First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer.
Aktürk Esen S, Ergun Y, Erol C, Arikan R, Er MM, Atci MM, Topçu A, Uçar G, Akagündüz B, Aykan MB, Özen M, Baytemur NK, Özçelik M, Şahin E, Güven D, Menekşe S, Ak N, Teker F, Kut E, Şakalar T, Alan Ö, Kaçan T, Turhal NS, Kiliçkap S, Türker S, Şendur MAN, Köstek O, Karaağaç M, Sakin A, Türk HM, Çağlayan D, Cihan Ş, Açikgöz Y, Uncu D. Aktürk Esen S, et al. Among authors: turker s. Bosn J Basic Med Sci. 2022 Sep 16;22(5):818-825. doi: 10.17305/bjbms.2021.7069. Bosn J Basic Med Sci. 2022. PMID: 35460397 Free PMC article.
107 results